1. Home
  2. UHG vs TECX Comparison

UHG vs TECX Comparison

Compare UHG & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Homes Group Inc

UHG

United Homes Group Inc

N/A

Current Price

$1.18

Market Cap

68.8M

ML Signal

N/A

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

N/A

Current Price

$33.73

Market Cap

393.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
UHG
TECX
Founded
N/A
2019
Country
United States
United States
Employees
175
51
Industry
Homebuilding
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
68.8M
393.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
UHG
TECX
Price
$1.18
$33.73
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$80.40
AVG Volume (30 Days)
626.4K
434.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$13.70
52 Week High
$4.78
$35.99

Technical Indicators

Market Signals
Indicator
UHG
TECX
Relative Strength Index (RSI) 33.99 70.89
Support Level $1.14 $16.83
Resistance Level $1.81 N/A
Average True Range (ATR) 0.03 2.64
MACD -0.02 1.12
Stochastic Oscillator 28.57 85.97

Price Performance

Historical Comparison
UHG
TECX

About UHG United Homes Group Inc

United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: